For physicians
For expectant parents
For physicians
For expectant parents
The Harmony® Test
The Harmony® Test can reliably detect the risk of the chromosomal disorders trisomy 21, trisomy 18, trisomy 13 as well as X- and Y-chromosomal disorders and DiGeorge syndrome. All aspects of the Harmony® Test are carried out according to european standards of quality and data protection.
Expert opinions on non-invasive prenatal screening test (NIPT)
Performing Harmony® Test
Advantages of the Harmony® Test
Excellent detection rate for trisomy 21, 18 and 13
Very low false-positive rate
Fast turnaround time
Excellent clinical validation in studies with more than 148.000 patients
Affordable price
Feasibility under heparin treatment
Latest News
Genome-wide tests from cfDNA
Genomweite Tests aus cfDNA 13. Mai 2020 Seit einiger Zeit werden sog. NIPT-Verfahren angeboten, die alle 23 Chromosomenpaare untersuchen (sog. genomweites Testen, GW-cfDNA testing). In diesem Zusammenhang möchten wir Sie auf eine bemerkenswerte Publikation aus der Arbeitsgruppe um Prof. Nicolaides hinweisen [1], in der die Ergebnisse der niederländischen TRIDENT-2 Studie und einer Studie aus Belgien bewertet werden.
Discontinuation of the test option microdeletion 22q11.2 (DiGeorge syndrome)
Discontinuation of the test option microdeletion 22q11.2 (DiGeorge syndrome) 28. March 2022 We have been analyzing the 22q11.2 microdeletion 22q11.2 (DiGeorge syndrome) as part of the Harmony® Test since July 2018. We now evaluated the data from more than 50000 cases. The evaluation of the data shows that of the cases tested positive for DiGeorge syndrome
Analysis of the Harmony Test from April 1st, 2022 exclusively in Tübingen, Germany
Analysis of the Harmony Test from April 1st, 2022 exclusively in Tübingen, Germany 25. March 2022 We are pleased to inform you that due to the expansion of our laboratory space, all incoming samples will be processed in our Lab in Tübingen from April 1st, 2022. Analysis of the Harmony Test from April 1st, 2022 exclusively in
The Harmony® Test
The Harmony® Test can reliably detect the risk of the chromosomal disorders trisomy 21, trisomy 18, trisomy 13 as well as X- and Y-chromosomal disorders and DiGeorge syndrome. All aspects of the Harmony® Test are carried out according to european standards of quality and data protection.
Expert opinions on non-invasive prenatal screening test (NIPT)
Durchführung Harmony Test
Advantages of the Harmony® Test
Excellent detection rate for trisomy 21, 18 and 13
Very low false-positive rate
Fast turnaround time
Excellent clinical validation in studies with more than 148.000 patients
Affordable price
Feasibility under heparin treatment
Latest News
Genome-wide tests from cfDNA
Genomweite Tests aus cfDNA 13. Mai 2020 Seit einiger Zeit werden sog. NIPT-Verfahren angeboten, die alle 23 Chromosomenpaare untersuchen (sog. genomweites Testen, GW-cfDNA testing). In diesem Zusammenhang möchten wir Sie auf eine bemerkenswerte Publikation aus der Arbeitsgruppe um Prof. Nicolaides hinweisen [1], in der die Ergebnisse der niederländischen TRIDENT-2 Studie und einer Studie aus Belgien bewertet werden.
Discontinuation of the test option microdeletion 22q11.2 (DiGeorge syndrome)
Discontinuation of the test option microdeletion 22q11.2 (DiGeorge syndrome) 28. March 2022 We have been analyzing the 22q11.2 microdeletion 22q11.2 (DiGeorge syndrome) as part of the Harmony® Test since July 2018. We now evaluated the data from more than 50000 cases. The evaluation of the data shows that of the cases tested positive for DiGeorge syndrome
Analysis of the Harmony Test from April 1st, 2022 exclusively in Tübingen, Germany
Analysis of the Harmony Test from April 1st, 2022 exclusively in Tübingen, Germany 25. March 2022 We are pleased to inform you that due to the expansion of our laboratory space, all incoming samples will be processed in our Lab in Tübingen from April 1st, 2022. Analysis of the Harmony Test from April 1st, 2022 exclusively in
The Harmony® Test
The Harmony® Test can reliably detect the risk of the chromosomal disorders trisomy 21, trisomy 18, trisomy 13 as well as X- and Y-chromosomal disorders and DiGeorge syndrome. All aspects of the Harmony® Test are carried out according to european standards of quality and data protection.
Expert opinions on non-invasive prenatal screening test (NIPT)
Durchführung Harmony Test
Advantages of the Harmony® Test
Excellent detection rate for trisomy 21, 18 and 13
Very low false-positive rate
Fast turnaround time
Excellent clinical validation in studies with more than 148.000 patients
Affordable price
Feasibility under heparin treatment
Latest News
Genome-wide tests from cfDNA
Genomweite Tests aus cfDNA 13. Mai 2020 Seit einiger Zeit werden sog. NIPT-Verfahren angeboten, die alle 23 Chromosomenpaare untersuchen (sog. genomweites Testen, GW-cfDNA testing). In diesem Zusammenhang möchten wir Sie auf eine bemerkenswerte Publikation aus der Arbeitsgruppe um Prof. Nicolaides hinweisen [1], in der die Ergebnisse der niederländischen TRIDENT-2 Studie und einer Studie aus Belgien bewertet werden.
Discontinuation of the test option microdeletion 22q11.2 (DiGeorge syndrome)
Discontinuation of the test option microdeletion 22q11.2 (DiGeorge syndrome) 28. March 2022 We have been analyzing the 22q11.2 microdeletion 22q11.2 (DiGeorge syndrome) as part of the Harmony® Test since July 2018. We now evaluated the data from more than 50000 cases. The evaluation of the data shows that of the cases tested positive for DiGeorge syndrome
Analysis of the Harmony Test from April 1st, 2022 exclusively in Tübingen, Germany
Analysis of the Harmony Test from April 1st, 2022 exclusively in Tübingen, Germany 25. March 2022 We are pleased to inform you that due to the expansion of our laboratory space, all incoming samples will be processed in our Lab in Tübingen from April 1st, 2022. Analysis of the Harmony Test from April 1st, 2022 exclusively in
Procedure of the Harmony® Test
Genetic counseling
Patient requests the Harmony® Test and gets a genetic counseling by obstetrician or human geneticist
Blood sample
Shipping
Test performance
